Play all audios:
Galmiche JP _et al_. (2005) A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. _Aliment Pharmacol Ther_ 21:
575–582 Proton-pump inhibitors (PPIs) effectively prevent gastric-acid secretion and are used to control the symptoms of various acid-related gastrointestinal diseases. These compounds have
a short plasma half-life, however, which limits the efficacy of a single dose. The novel PPI tenatoprazole, an imidazopyridine derivative, benefits from an extended plasma half-life and
could negate the requirement for repeated dosing. Galmiche _et al_. have recently compared the effects of tenatoprazole with esomeprazole, a benzimidazole-derived PPI, on intragastric pH in
healthy subjects. The randomized, two-period crossover study recruited 24 healthy, male volunteers from a French academic institution. All subjects had no history of gastrointestinal disease
and tested negative for _Helicobacter pylori_, HIV, and hepatitis B and C. Volunteers received either 40 mg tenatoprazole (T40) or esomeprazole 40 mg (E40) once daily for 2 consecutive days
and, after a 2-week interim period, changed to the other regimen. All volunteers were hospitalized and intragastric pH was monitored every 5 s during the 48-hour dosing period. Nocturnal pH
levels were significantly higher on both the first and second days in subjects receiving T40 when compared with those receiving E40, although this effect was not observed diurnally. T40 was
also significantly more effective than E40 at reducing the duration of nocturnal acid breakthroughs. The time needed to reach a sustained increase in intragastric pH was, however,
comparable for both drugs. The authors conclude that tenatoprazole is a potent acid suppressor and, in the first 48 h, exerts significantly better control over nocturnal intragastric pH than
esomeprazole. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Superior control of nocturnal gastric-acid secretion by the novel proton-pump inhibitor,
tenatoprazole. _Nat Rev Gastroenterol Hepatol_ 2, 202 (2005). https://doi.org/10.1038/ncpgasthep0163 Download citation * Issue Date: 01 May 2005 * DOI: https://doi.org/10.1038/ncpgasthep0163
SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy
to clipboard Provided by the Springer Nature SharedIt content-sharing initiative